Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit on Wednesday, but rising competition is weighing on sales of its diabetes and obesity treatments Ozempic and ...

Novo Nordisk (NVO) offered investors an update about ongoing cost-cutting efforts as copycat weight-loss drugs weigh on sales ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Even though Novo Nordisk warned that copycat versions of its obesity and diabetes drugs would hurt sales in the U.S., second-quarter sales saw a 67% rise year on year. More news covers telehealth ...

Stephen Millard, a senior economist at NIESR, said: “We think the current budget deficit will be around £40bn, or £41.2bn to ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

STORY: Novo Nordisk said Wednesday it would cut costs as it takes on growing competition.The Danish firm faces a growing ...

Shares of Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, fell in pre-market trading and on the ...

The outgoing chief executive of Novo Nordisk has revealed plans to ramp-up cost cutting 'efficiencies' across the business, ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit today, but rising competition is ...